Medscape Medical News > Conference News > EASD 2024 Becky McCall September 12, 2024 MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to phase 1, first-in-human study data presented at the European Association for the Study of Diabetes...
Tag: <span>Weight loss</span>
Semaglutide and tirzepatide lead to better blood sugar control and weight loss in type 1 diabetes, study finds
September 12, 2024 by Diabetologia Credit: Unsplash/CC0 Public DomainSemaglutide and tirzepatide treatment lead to significant weight loss and improve blood sugar control in individuals with type 1 diabetes (T1D) who are living with overweight or obesity, research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) held in Madrid,...
Predictors for achieving, sustaining blood glucose control, weight loss with tirzepatide in adults with type 2 diabetes
September 11, 2024 by Diabetologia Credit: Pixabay/CC0 Public DomainThe phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D). Now new research examining a broad range of potential predictors of sustaining blood sugar control and weight...
Analysis finds no increased risk of mental health issues among those using semaglutide for weight loss
September 3, 2024 by Perelman School of Medicine at the University of Pennsylvania Credit: Unsplash/CC0 Public DomainTaking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School...
Zapping Hunger: The Next Big Thing in Weight Loss?
By National Research Council of Science & TechnologyAugust 24, 2024 Dr. Ki-young Shin’s team at KERI is advancing research on neuromodulation technology, specifically transcranial random noise stimulation (tRNS), to treat metabolic syndrome by suppressing appetite through non-invasive electrical stimulation. Their clinical trials have shown promising results in reducing appetite and emotional eating, with further phases...
Can B12 Shots Help With Weight Loss?
Written by Tracy Norfleet, MD, MBA, FACP, ABOM | Reviewed by Patricia Pinto-Garcia, MD, MPHPublished on June 10, 2024 Key takeaways: Vitamin B12 is an essential vitamin that your body needs to function properly. You can get enough vitamin B12 from either food or supplements, like vitamin B12 shots.People with a BMI over 30 can...
Only 1 in 4 still taking Ozempic, Wegovy for weight loss two years later
JULY 11, 2024 by Robin Foster Three of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weight loss, a new analysis shows. Conducted by Prime Therapeutics and Magellan Rx Management (MRx), the review sifted through pharmacy and medical claims data for 3,364 people with insurance plans that...
Older weight loss drugs are in demand. But are they safe or effective? And should you take them?
by Cynthia McCormick Hibbert, Northeastern University Credit: Unsplash/CC0 Public Domain With Ozempic-type weight loss drugs in short supply, more people are turning to old-school weight loss drugs such as Qsymia and Contrave, which come in pill form but also include serious warning labels. Savanna DiCristina, a Northeastern assistant clinical professor of pharmacy and health systems...
Popular prescription weight loss drugs linked to uncommon blinding condition
NEWS RELEASE 3-JUL-2024 A new Mass Eye and Ear-led study is the first to discover that people prescribed semaglutide, sold as Ozempic and Wegovy, have a higher risk of developing a form of blindness due to optic nerve disease known as non-arteritic anterior ischemic optic neurop Peer-Reviewed PublicationMASS EYE AND EAR A new study led...
Weight loss surgery cuts risk of heart complications and death in patients with obstructive sleep apnea and obesity
by Cleveland Clinic Credit: Unsplash/CC0 Public Domain A Cleveland Clinic study shows that bariatric surgery performed in patients with obesity and moderate to severe obstructive sleep apnea is associated with a significantly lower risk of death and major adverse cardiovascular events, compared with patients who did not have the surgery. This study was published in...